Research Insights
Research Insights section focuses on the cutting-edge and breakthrough research that is happening all over the world. Laboratories across the globe are working hard to develop drugs and therapies for various diseases and research insights directly from them add tremendous value.
Progress And Perspectives On Targeting Nanoparticles For Brain Drug Delivery
Abstract Due to the ability of the bloodbrain barrier BBB to prevent the entry of drugs into the brain it is a challenge to treat central nervous system disorders pharmacologically The development of nanotechnology provides potential to overcome this problem In this review the barriers to braintargeted drug delivery are reviewed including the BBB
PBPK Modeling And Simulation In Drug Research And Development
Abstract Physiologically based pharmacokinetic PBPK modeling and simulation can be used to predict the pharmacokinetic behavior of drugs in humans using preclinical data It can also explore the effects of various physiologic parameters such as age ethnicity or disease status on human pharmacokinetics as well as guide dose and dose regiment selecti...
Structure-based Drug Discovery For Prion Disease Using A Novel Binding Simulation
Abstract The accumulation of abnormal prion protein PrPSc converted from the normal cellular isoform of PrP PrPC is assumed to induce pathogenesis in prion diseases Therefore drug discovery studies for these diseases have focused on the protein conversion process We used a structurebased drug discovery algorithm termed Nagasaki University Docking...
Preparation And Application Of Functionalized Nano Drug Carriers
Abstract Objective Targeting at category memory characteristics and preparation methods of functionalized nano drugs preparation technology of functionalized nano drug carriers is studied and then important role of functionalized nano drug carrier in preparation of medicine is studied Methods
Challenges And Strategies In Anti-cancer Nanomedicine Development: An Industry Perspective
Abstract Successfully translating anticancer nanomedicines from preclinical proof of concept to demonstration of therapeutic value in the clinic is challenging Having made significant advances with drug delivery technologies we must learn from other areas of oncology drug development where patient stratification and targetdriven design have improv...
Design of experiment based validated stability indicating RP-HPLC method of temozolomide in bulk and pharmaceutical dosage forms
Abstract A simple precise stability indicating RPHPLC method was developed and validated for determination of Temozolomide TMZ in bulk sample and nanostructured lipid carriers A BoxBehnken statistical design with three factors and three levels was employed to optimize the chromatographic conditions The separation was achieved using solvent system...
Ion-pairing HPLC methods to determine EDTA and DTPA in small molecule and biological pharmaceutical formulations
Abstract Ionpairing highperformance liquid chromatographyultraviolet HPLCUV methods were developed to determine two commonly used chelating agents ethylenediaminetetraacetic acid EDTA in Abilify a small molecule drug with aripiprazole as the active pharmaceutical ingredient oral solution and diethylenetriaminepentaacetic acid DTPA in Y
Temperature Excursion Management – A Novel Approach Of Quality System In Pharmaceutical Industry
Abstract Quality of pharmaceutical product largely depends upon by the environment controls during its storage and handling Each pharmaceutical product should be handled and stored under specified storage condition labelled on product information data sheet or product pack Hence the temperature excursions during receipt of raw materials manufactur...
A Simple And Sensitive Method To Analyze Genotoxic Impurity Hydrazine In Pharmaceutical Materials
Abstract Hydrazine NH is a known genotoxic impurity that typically needs to be controlled down to low ppm level in pharmaceutical development Hydrazine however is a challenging molecule to analyze using conventional analytical techniques due to its physical and chemical properties eg lack of chromophore absence of any carbon atom low molecular wei...
New Developments For Antibody-drug Conjugate-based Therapeutic Approaches
Abstract The clinical success of Adcetris brentuximab vedotin and Kadcyla adotrastuzumab emtansine has sparked clinical development of novel ADCs These powerful anticancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues Despite the use of tumorspecific antibodies
